Table 1:
Patient Demographics
| MSKCC Discovery Set | PROPHECY Validation set | |
|---|---|---|
| Unique Patients, no. (%) | 171 | 107 |
| Unique Blood Samples, no. (%) | 171 | 107 |
| Median Age in years (range) | 68 (45,87) | 73 (44,92) |
| Death events, no. (%) | 138 (80.7%) | 83 (77.6%) |
| Median Follow Up of Survivors in months (range) | 56.5 (5.0, 84.2) | 31 (3.4, 42.3) |
| Therapy Line - no. (%) | ||
| pre-1st | 103 (60.2%) | 76 (71%) |
| pre-2nd | 49 (28.7%) | 31 (29%) |
| pre-3rd | 19 (11.1%) | 0 (0%) |
| Sites of Metastases – no. (%) | ||
| Lymph Node Only | 24 (14.0% | 3 (2.8%) |
| Bone Only | 59 (34.5%) | 23 (21.5%) |
| Lung Only | 1 (0.6%) | 0 (0%) |
| Multiple Sites | 88 (51.5%) | 79 (73.8%) |
| Prior Taxane Chemotherapy – no. (%) | 14 (8.2%) | 20 (18.7%) |
| Prior ARSi – no. (%) | 60 (35.1%) | 40 (37.4%) |
| Baseline lab values - median (range) | ||
| PSA ng/mL | 18.1 (0.0900, 2010) | 22.1 (0.1, 4194.9) |
| ALB g/L | 4.2 (3.3, 4.9) | 4.0 (2.7, 4.9) |
| ALK U/L | 96 (42, 2170) | 110 (91, 150) |
| HGB g/dL | 12.6 (8.2, 15.7) | 12.8 (8.7, 15.9) |
| LDH U/L | 208 (124, 2120) | 200 (100, 618) |
| WBC x 109/L | 5.9 (2.6, 12.1) | 6.4 (3.7, 22.3) |
| CellSearch® CTC count/7.5mL | n/a | 4 (0, 12,972) |
Abbreviations: PSA - prostate specific antigen, ALB - albumin, ALK - alkaline phosphatase, HGB - hemoglobin, LDH - lactate dehydrogenase, WBC - white blood cell